Clinical trial NCT03172559: Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)
Official title: A Multi-Center Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy as a "Bridge" Prior to Liver Transplant for Hepatocellular Carcinoma Versus no Intervention in Patients Not Eligible to Transarterial Chemoembolization or Ablation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hepatocellular Carcinoma
Keywords: Stereotactic body radiotherapy
SBRT
Radiotherapy
Bridging therapy
Transplant
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2017-06-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Explanatory, multicenter, open label, 2-arm parallel group superiority randomized trial with stratification by center and blood group, random permuted blocks (lengths of 4 or 6) and balanced allocation (1:1).
Primary purpose: TREATMENT

Brief summary: Liver transplantation (LT) represents the best treatment for patients with selected, early stage hepatocellular carcinoma (HCC). Due to the gap between the number of patients on the waiting list and the available donors, patients with HCC wait \~1 year to be transplanted. While waiting, 25-30% of patients need to come off the transplant list due to tumor progression beyond transplant criteria (extrahepatic disease, vascular invasion or increase in tumor burden beyond enlistment criteria). To try to avoid this progression, patients are treated while waiting with "bridging therapies", mainly transarterial chemoembolization (TACE) and ablation. Around 30% of patients are not eligible for these treatments (.e.g. due to poor liver function). Stereotactic body radiotherapy (SBRT) has been shown to be an effective treatment for advanced HCC in primarily small, single institutional studies and its safety has been reported in cirrhotics. SBRT could be used in patients not eligible to TACE or ablation as a bridge to LT reducing the risk of progression in the waiting list. This study will evaluate if patients with liver cirrhosis and HCC benefit from receiving SBRT while awaiting LT. Patients will be randomized to a treatment arm where they will receive SBRT as a bridge therapy or to a no intervention arm. Outcomes prior and post to transplant will be performed to evaluate the differences between both arms: proportion of patients that do not drop-out of the list (are transplanted), liver decompensation while waiting, perioperative measures in those that are transplanted, time to transplant or drop-out, overall survival, disease-free survival in those that are transplanted in a population of about 330 patients across all sites.

Detailed description: The RADBRI trial is designed as an explanatory, multicenter, open-label, 2-arm parallel group superiority randomized trial with stratification by center and blood group, random permuted blocks (lengths of 4 or 6) and balanced allocation (1:1) conducted in 8 centers across the world. Including a population of adult patients with hepatocellular carcinoma (HCC) included in the waiting list for a liver transplant (LT) that are not eligible for transarterial chemoembolization (TACE) or ablation as a bridge to transplant but are eligible to stereotactic body radiotherapy (SBRT). Participants will be randomly assigned to either no intervention or SBRT with a 1:1 allocation as per an online, central randomization service (Sealed Envelope™) and stratified by site and by blood type (ABO type) using random permuted blocks (lengths 4 or 6). Aiming for a total sample of 332 (166 per group). Patients will be followed for 18 months until drop-out from waiting list or LT. A computed tomography (CT) or magnetic resonance imaging (MRI) and alpha-fetoprotein (AFP) level will be performed every 3 months while waiting. In those that get transplanted, follow-up will be carried out for additional 36 months (every 3 months for the first 2 years and every 6 months thereafter).

Eligibility criteria: Inclusion Criteria:

* 18-75 years old
* Patient has been included in the waiting list to receive a Liver Transplant (LT)
* Radiological confirmation of Hepatocellular carcinoma (HCC) according to American Association for the Study of Liver Diseases (AASLD) guidelines
* Tumor burden at randomization within a total tumor volume (TTV) ≤115 cm3 and serum alpha-fetoprotein (AFP) ≤400 ng/mL
* Patient not eligible to bridging therapy with Transarterial Chemoembolization (TACE) and/or ablation.
* Child-Pugh score ≤B9
* Calculated Model of End Stage Liver disease (MELD) score ≤20
* Eligible to Stereotactic body radiotherapy (SBRT): \>40% of liver parenchyma can be spared from radiation and all tumors can be targeted
* No previous treatment of the tumor
* Absence of extra-hepatic disease or vascular invasion on imaging
* Able and willing to provide consent

Exclusion Criteria:

* Patient with HCC not candidate to receive a LT
* Patient is eligible to TACE or ablation as a bridge to LT
* Patient is not eligible to SBRT
* Previous bridging therapies

Primary outcomes:
measure: Difference between the two treatment arms in the proportion of participants that get to be transplanted (do not drop-out from the waiting list due to tumor progression).
timeFrame: 5 years
Secondary outcomes:
measure: Difference between the two arms in liver decompensation while waiting
timeFrame: 5 years
measure: Difference between the two arms in perioperative measures
timeFrame: 5 years
measure: Difference between the two arms in time to transplant or drop-out
timeFrame: 5 years
measure: Difference between the two arms in overall survival
timeFrame: 5 years
measure: Difference between the two arms in overall survival
timeFrame: 5 years
measure: Difference between the two arms in disease-free survival
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
affiliation: University Health Network, Toronto
name: Gonzalo Sapisochin, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Health Network, Toronto
name: Laura Dawson, MD
role: PRINCIPAL_INVESTIGATOR
References: